Results 71 to 80 of about 17,670,994 (229)

Neovascular glaucoma at a tertiary Centre in Finland, 2008–2024: A retrospective cohort study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Neovascular glaucoma (NVG) is a refractory secondary glaucoma, yet longitudinal outcome data remain limited. This study reports its aetiologies, treatments and outcomes. Methods Patients with NVG were identified through electronic medical record review.
Gilbert Simons, Mikael von Fersen, Paula Summanen, Mika Harju   +3 more
wiley   +1 more source

Marginal zone lymphoma presenting with chylous ascites: A rare clinical manifestation and successful treatment with orelabrutinib–rituximab

SAGE Open Medical Case Reports
Marginal zone lymphoma is the second most common subtype of indolent non-Hodgkin lymphoma. Its clinical manifestations are heterogeneous and largely determined by the involved site.
Jie Wu, Feng-jing Wang, Zhi-dong Jia, Yang-qiu Li, Li-ye Zhong   +4 more
doaj   +1 more source

Blastic Transformation of Splenic Marginal Zone B-Cell Lymphoma

Archives of Pathology & Laboratory Medicine, 2000
Abstract To our knowledge, blastic transformation of splenic marginal zone lymphoma, a recently characterized low-grade lymphoproliferative disorder, has not been reported previously. In this regard, we report the unique case of a 70-year-old woman whose untreated splenic marginal zone lymphoma underwent blastic transformation 3 years
H, Cualing, P, Steele, D, Zellner
openaire   +2 more sources

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Molecular mechanisms of follicular lymphoma and its transformation [PDF]

, 2011
PhDFollicular lymphoma (FL) is the second most common form of non-Hodgkin lymphoma and at least a third of cases undergo aggressive transformation (t-FL), most frequently to diffuse large B-cell lymphoma.
Wrench, David John
core   +3 more sources

DNA methylation in follicular lymphoma [PDF]

, 2010
PhDFollicular Lymphoma (FL) is a common B cell Non-Hodgkin Lymphoma with a median survival of 8-10 years. Patients frequently undergo transformation to a more aggressive lymphoma and this is associated with drastically reduced survival.
Ó Riain, Ciarán Liam
core   +3 more sources

Retrospective study of canine non-Hodgkin lymphoma cases diagnosed from samples originating in northeastern Brazil (2012-2022) [PDF]

Pesquisa Veterinária Brasileira
: Lymphoma is a malignant hematopoietic neoplasm that affects canines. Its classification is based on anatomical, histomorphological, cytomorphological, and immunophenotypic characteristics.
Saulo R.F. Gonçalves, Dyeime R. Sousa, Ricardo B. Lucena, Lorena G.R. Ribeiro, Rachel L.F.S. Andrade, Daniel A. Viana, Carlos H.C. Vieira-Filho, Silvana M.M.S. Silva, Telma D. Lima, Andrea A.F. Oliveira, Francisco A.L. Souza   +10 more
doaj   +2 more sources

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

British Journal of Haematology, EarlyView.
Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari, Maria Elena Nizzoli, Michele Merli, Sara Rattotti, Vittoria Tarantino, Simone Ferrero, Annalisa Talami, Roberta Murru, Marina Deodato, Emanuele Cencini, Giovanni Roti, Carlo Visco, Guilherme Duffles, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés José María Ferreri, Caterina Stelitano, Elsa Pennese, Emiliano Barbieri, Marzia Varettoni, Gambara Silvia, Marta Coscia, Dario Marino, Tisi Maria Chiara, Maher Nawar, Luigi Marcheselli, Francesco Merli, Luca Arcaini   +28 more
wiley   +1 more source

The potential therapeutic role of selenium in diffuse large B-cell lymphoma [PDF]

, 2011
PhDThe clinical background to this work confirms the very poor outcome of patients with recurrent diffuse large B-cell lymphoma (DLBCL) and highlights the need for better therapies.
Kassam, Shireen
core   +3 more sources

Biopsy of Iris and Anterior Chamber Tumours: Fine Needle, Minimally Invasive and Excision Techniques ‐ Review

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Several benign, inflammatory and malignant lesions can present as iris or anterior chamber masses, including iris naevi, cysts, adenomas, leiomyomas, nodules, vascular tumours, melanomas, metastases, as well as iris and pigment epithelium adenocarcinomas. Fortunately, benign iris lesions are much more common than malignant tumours and many can
Charles N. J. McGhee, Joevy Z. Lim, Peter W. Hadden, Jie Zhang   +3 more
wiley   +1 more source